Thea Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for THEA PHARMA, and what generic alternatives to THEA PHARMA drugs are available?
THEA PHARMA has seven approved drugs.
There are four US patents protecting THEA PHARMA drugs.
There are ninety-four patent family members on THEA PHARMA drugs in thirty-four countries and twenty-one supplementary protection certificates in ten countries.
Drugs and US Patents for Thea Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | 10,864,159 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Thea Pharma | IYUZEH | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 216472-001 | Dec 13, 2022 | RX | Yes | Yes | 8,637,054 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Thea Pharma | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | AT | RX | Yes | Yes | 9,999,593 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Thea Pharma | AZASITE | azithromycin | SOLUTION/DROPS;OPHTHALMIC | 050810-001 | Apr 27, 2007 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Thea Pharma | COSOPT PF | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 202667-001 | Feb 1, 2012 | AT2 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Thea Pharma | BETIMOL | timolol | SOLUTION/DROPS;OPHTHALMIC | 020439-001 | Mar 31, 1995 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Thea Pharma | COSOPT | dorzolamide hydrochloride; timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 020869-001 | Apr 7, 1998 | AT1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Thea Pharma
Paragraph IV (Patent) Challenges for THEA PHARMA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Ophthalmic Solution | 2%/0.5% | ➤ Subscribe | 2005-10-11 |
➤ Subscribe | Ophthalmic Solution | 1% | ➤ Subscribe | 2011-03-03 |
➤ Subscribe | Ophthalmic Solution | 0.0015% | ➤ Subscribe | 2016-02-10 |
International Patents for Thea Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 6356868 | ⤷ Sign Up |
Slovenia | 3205334 | ⤷ Sign Up |
Croatia | P20140979 | ⤷ Sign Up |
Poland | 3714877 | ⤷ Sign Up |
South Korea | 102246598 | ⤷ Sign Up |
Spain | 2495316 | ⤷ Sign Up |
Croatia | P20170769 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Thea Pharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0850926 | SPC/GB09/005 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017 |
3461484 | 301101 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
0364417 | 61/1997 | Austria | ⤷ Sign Up | PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718 |
3461484 | SPC/GB21/033 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107 |
0850926 | 11C0020 | France | ⤷ Sign Up | PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430 |
0364417 | SPC/GB97/014 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
0364417 | C970039 | Netherlands | ⤷ Sign Up | PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.